PAX-1 is under clinical development by Komipharm International and currently in Phase I for Multiple Myeloma (Kahler Disease). According to GlobalData, Phase I drugs for Multiple Myeloma (Kahler Disease) have a 77% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how PAX-1’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

PAX-1 overview

PAX-1 is under development for the treatment of cancer pain, inflammatory pain, neuropathic pain, newly diagnosed glioblastoma and recurrent glioblastoma and non-small cell lung carcinoma, lymph non-small cell lung carcinoma, metastatic breast cancer, metastatic soft-tissue cancer, metastatic osteosarcoma, metastatic gastric cancer, metastatic renal cancer, metastatic ovarian cancer, metastatic bladder cancer, metastatic cervical cancer, metastatic endometrial cancer, metastatic head and neck cancer, metastatic prostate cancer, malignant melanoma, cholangiocarcinoma, prostate cancer and multiple myeloma, brain cancer and coronavirus disease 2019 (covid-19) pneumonia. It is a non narcotic cancer pain reliever. The drug candidate is arsenic oxide. It administered through oral route as a tablet. It acts by targeting IL-18 and IL-1B.

Komipharm International overview

Komipharm International (Komipharm) provides pharmaceutical and animal health products. The company’s product pipeline includes PAX-1-001, a non-opioid drug candidate designed to treat cancer pain; PAX-1-002 for treating brain cancer; PAX-1-004 against gallbladder, prostate cancer and multiple myeloma; KML001 an oral drug used for the treatment of prostate, solid, biliary tract, lung and liver cancer and malignant lymphoma; PAX-1-003, to treat lung to brain metastases, head and neck cancer, metastatic melanoma, osteosarcoma and soft tissue cancer. It also develops vaccines and medical products for treating fever, pain, skin problems and other diseases in animals. Komipharm works in partnership with other pharmaceutical companies worldwide to develop its pipeline products. The company operates production facilities in Australia, the US and South Korea. Komipharm is headquartered in Siheung, South Korea

For a complete picture of PAX-1’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.